Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Xeris Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $34.81M, up 25.3% year over year. For fiscal 2025 it was $31.17M, up 21.9% from the year before. The highest annual figure on record is $31.17M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.17M | +21.9% |
| FY2024 | Dec 31, 2024 | $25.56M | +14.4% |
| FY2023 | Dec 31, 2023 | $22.34M | +6.6% |
| FY2022 | Dec 31, 2022 | $20.97M | -16.7% |
| FY2021 | Dec 31, 2021 | $25.16M | +20.3% |
| FY2020 | Dec 31, 2020 | $20.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.67M | +32.5% |
| Q1 FY2026 | Mar 31, 2026 | $8.78M | +13.3% |
| Q4 FY2025 | Dec 31, 2025 | $7.87M | +29.3% |
| Q3 FY2025 | Sep 30, 2025 | $7.48M | +27.1% |
| Q2 FY2025 | Jun 30, 2025 | $8.06M | +39.9% |
| Q1 FY2025 | Mar 31, 2025 | $7.75M | -0.9% |
| Q4 FY2024 | Dec 31, 2024 | $6.09M | -4.5% |
| Q3 FY2024 | Sep 30, 2024 | $5.89M | +17.0% |
| Q2 FY2024 | Jun 30, 2024 | $5.76M | -5.4% |
| Q1 FY2024 | Mar 31, 2024 | $7.82M | +61.7% |
| Q4 FY2023 | Dec 31, 2023 | $6.38M | +28.8% |
| Q3 FY2023 | Sep 30, 2023 | $5.03M | -16.7% |
| Q2 FY2023 | Jun 30, 2023 | $6.09M | +63.7% |
| Q1 FY2023 | Mar 31, 2023 | $4.84M | -22.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.96M | -50.9% |
| Q3 FY2022 | Sep 30, 2022 | $6.04M | +6.7% |
| Q2 FY2022 | Jun 30, 2022 | $3.72M | -30.9% |
| Q1 FY2022 | Mar 31, 2022 | $6.25M | +55.0% |
| Q4 FY2021 | Dec 31, 2021 | $10.08M | +97.3% |
| Q3 FY2021 | Sep 30, 2021 | $5.66M | +46.1% |
| Q2 FY2021 | Jun 30, 2021 | $5.38M | – |
| Q1 FY2021 | Mar 31, 2021 | $4.03M | – |
| Q4 FY2020 | Dec 31, 2020 | $5.11M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.88M | – |
See a number that looks wrong?